PMC:7600245 / 49662-50215
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T219 | 97-102 | Body_part | denotes | bowel | http://purl.org/sig/ont/fma/fma7199 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T213 | 84-110 | Disease | denotes | inflammatory bowel disease | http://purl.obolibrary.org/obo/MONDO_0005265 |
| T214 | 112-130 | Disease | denotes | multiple sclerosis | http://purl.obolibrary.org/obo/MONDO_0005301 |
| T215 | 159-178 | Disease | denotes | autoimmune diseases | http://purl.obolibrary.org/obo/MONDO_0007179 |
| T216 | 506-514 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T493 | 16-17 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T494 | 200-201 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T495 | 332-333 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T25593 | 34-42 | Chemical | denotes | molecule | http://purl.obolibrary.org/obo/CHEBI_25367 |
| T7933 | 202-210 | Chemical | denotes | biphenyl | http://purl.obolibrary.org/obo/CHEBI_17097 |
| T40831 | 211-220 | Chemical | denotes | carbamoyl | http://purl.obolibrary.org/obo/CHEBI_23004|http://purl.obolibrary.org/obo/CHEBI_33100 |
| T2210 | 221-233 | Chemical | denotes | cyclopentene | http://purl.obolibrary.org/obo/CHEBI_49155 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T48 | 84-110 | Phenotype | denotes | inflammatory bowel disease | http://purl.obolibrary.org/obo/HP_0002037 |
| T49 | 159-178 | Phenotype | denotes | autoimmune diseases | http://purl.obolibrary.org/obo/HP_0002960 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T371 | 0-193 | Sentence | denotes | Vidofludimus is a synthetic small molecule that is under investigation for treating inflammatory bowel disease, multiple sclerosis, and other inflammatory and autoimmune diseases [154,155,156]. |
| T372 | 194-320 | Sentence | denotes | It is a biphenyl-carbamoyl-cyclopentene derivative (Figure 7) that is being developed as oral formulation for therapeutic use. |
| T373 | 321-553 | Sentence | denotes | Currently, a prospective, randomized, multi-center, double-blinded, and placebo-controlled study is ongoing to evaluate the safety and efficacy of vidofludimus as an adjunct therapy in COVID-19 patients (NCT04379271; n = 230) [157]. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1566 | 515-523 | Species | denotes | patients | Tax:9606 |
| 1567 | 0-12 | Chemical | denotes | Vidofludimus | MESH:C553728 |
| 1568 | 202-233 | Chemical | denotes | biphenyl-carbamoyl-cyclopentene | |
| 1569 | 468-480 | Chemical | denotes | vidofludimus | MESH:C553728 |
| 1570 | 84-110 | Disease | denotes | inflammatory bowel disease | MESH:D015212 |
| 1571 | 112-130 | Disease | denotes | multiple sclerosis | MESH:D009103 |
| 1572 | 159-178 | Disease | denotes | autoimmune diseases | MESH:D001327 |
| 1573 | 506-514 | Disease | denotes | COVID-19 | MESH:C000657245 |